This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Epizyme 관리

관리 기준 확인 2/4

주요 정보

Grant Bogle

최고 경영자

US$3.0m

총 보상

CEO 급여 비율	9.9%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	10.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Grant Bogle 의 보수는 Epizyme 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2022	n/a	n/a	-US$208m
Mar 31 2022	n/a	n/a	-US$236m
Dec 31 2021	US$3m	US$299k	-US$251m
Sep 30 2021	n/a	n/a	-US$267m
Jun 30 2021	n/a	n/a	-US$257m
Mar 31 2021	n/a	n/a	-US$251m
Dec 31 2020	US$196k	n/a	-US$232m
Sep 30 2020	n/a	n/a	-US$222m
Jun 30 2020	n/a	n/a	-US$202m
Mar 31 2020	n/a	n/a	-US$192m
Dec 31 2019	US$309k	n/a	-US$173m

보상 대 시장: Grant's total compensation ($USD3.01M) is above average for companies of similar size in the German market ($USD815.36K).

보상과 수익: Grant's compensation has increased whilst the company is unprofitable.

CEO

Grant Bogle (64 yo)

less than a year

테뉴어

US$3,011,807

보상

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

리더십 팀

이름	위치	테뉴어	보상	소유권
Grant Bogle	President	less than a year	US$3.01m	데이터 없음
Jeffery Kutok	Chief Scientific Officer	2.3yrs	US$2.86m	0.0080% $ 19.4k
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jerald Korn	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Joseph Beaulieu	Senior VP	4.1yrs	데이터 없음	0.0058% $ 13.9k
Craig West	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
John Weidenbruch	Senior VP	no data	데이터 없음	데이터 없음
Tanja Weber	Chief Business Officer	3.6yrs	데이터 없음	데이터 없음
Mark De Rosch	Chief Regulatory Officer	2.8yrs	데이터 없음	데이터 없음
Rebecca Mehrwerth	Senior VP & Head of Commercial	less than a year	데이터 없음	데이터 없음
Christoph Diefenbach	Laboratory Manager of Research & Development	no data	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: EPE's management team is considered experienced (2.3 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Grant Bogle	President	2.9yrs	US$3.01m	데이터 없음
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	데이터 없음	데이터 없음
George Daley	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
David Mott	Independent Chairman	12.7yrs	US$370.00k	0.19% $ 462.3k
Carl Goldfischer	Independent Director	12.9yrs	US$350.00k	0.0030% $ 7.2k
Christopher Walsh	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kenneth Bate	Independent Director	7.7yrs	US$330.94k	0% $ 0
Bruce Chabner	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ronald Evans	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Joel Huff	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Steven Henikoff	Member of the Scientific Advisory Board	no data	데이터 없음	데이터 없음

10.2yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: EPE's board of directors are seasoned and experienced ( 10.2 years average tenure).

This company listing is no longer active

Epizyme 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Independent Chairman recently bought €424k worth of stock

Independent Director recently bought €51k worth of stock

Epizyme, Inc. Announces Executive Promotions

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.63 loss in 2Q 2021)

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.69 loss in 1Q 2021)

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought €424k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.50

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: €9.30

Independent Director recently bought €51k worth of stock

New 90-day low: €9.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Epizyme, Inc. Announces Executive Promotions

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: €10.00

First half earnings released

New 90-day low - €11.60

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령